

APPLIED GENETIC TECHNOLOGIES CORP

FORM 8-K (Current report filing)

Filed 05/01/17 for the Period Ending 04/26/17

| | |
|-------------|--|
| Address | 14193 NW 119TH TERRACE SUITE #10 ALACHUA, FL 32615 |
| Telephone | 386-462-2204 |
| CIK | 0001273636 |
| Symbol | AGTC |
| SIC Code | 2836 - Biological Products, Except Diagnostic Substances |
| Industry | Biotechnology & Medical Research |
| Sector | Healthcare |
| Fiscal Year | 06/30 |

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): April 26, 2017

APPLIED GENETIC TECHNOLOGIES CORPORATION

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or other jurisdiction
of incorporation)

001-36370
(Commission
File Number)

59-3553710
(IRS Employer
Identification Number)

14193 NW 119 th Terrace
Suite 10
Alachua, Florida, 32165
(Address of principal executive offices) (Zip Code)

(386) 462-2204
(Registrant's telephone number, including area code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below).

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 26, 2017, Lawrence E. Bullock, our chief financial officer, notified us of his intention to retire in the near future. We have initiated a comprehensive search to identify candidates to succeed Mr. Bullock. He has indicated his willingness to continue to serve the company and facilitate a smooth transition to his successor.

We thank Mr. Bullock for his years of service and many contributions to the success of our company.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

APPLIED GENETIC TECHNOLOGIES CORPORATION

By: /s/ Susan B. Washer

Susan B. Washer
President and Chief Executive Officer

Date: May 1, 2017